Detalhe da pesquisa
1.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 23(10): 1308-1320, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36113498
2.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Lancet Oncol
; 20(11): 1531-1543, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31540791